HopeStage
Back to all studies
CompletedNCT04470050

BXCL501 for Symptoms of Opioid Withdrawal

About this titleRead the official source — NCT04470050
Medication studyAges 18–65United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Miami Lakes and 2 more locationsSee all locations and recruitment
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: June 9, 2020
Recruitment status
Completed
Enrollment listed in the registry
225
Sponsor
BioXcel Therapeutics Inc
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT04470050
Official title
Show the full official title

A Phase 1b/2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of BXCL501 to Treat Symptoms of Acute Opioid Withdrawal in Patients With Opioid Use Disorder Who Are Physically Dependent on Opioids

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Miami Lakes · Marlton · New York

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is BioXcel Therapeutics Inc.

Did this study involve medication?

Yes. The study involved medication, including Dexmedetomidine and Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies